



FDA ADVISORY  
No. **2020-184**

126 FEB 2020

**TO : ALL HEALTHCARE PROFESSIONALS AND THE GENERAL PUBLIC**

**SUBJECT : Public Health Warning Against the Purchase and Use of the Following Unregistered Drug Products:**

1. **Gastropin with Belladonna Tablet 120's**
2. **Ancom Tablets Anti-Hypertensive Compound Tablet 100's**
3. **Shilintong Tablets 100's**

The Food and Drug Administration (FDA) advises the public against the purchase and use of the following unregistered drug products:



**GASTROPIN WITH BELLADONNA TABLET 120's**  
Distributed by: **JIN LING ENTERPRISES**

Figure 1. Unregistered drug product





Figure 2. Unregistered drug product



Figure 3. Unregistered drug product

FDA Post-Marketing Surveillance (PMS) activities have verified that the abovementioned drug products have not gone through the registration and testing process of the Agency and have not been issued with proper authorization in the form of Certificate of Product Registration. Thus, the Agency cannot guarantee their quality and safety. Therefore, consumption of such violative product may pose potential danger or injury to health.

Pursuant to Republic Act No. 9711, otherwise known as the "Food and Drug Administration Act of 2009", the manufacture, importation, exportation, sale, offering for sale, distribution, transfer, promotion, advertising or sponsorship of health products without proper authorization from FDA is prohibited.


In light of the above, the public is advised not to purchase the aforementioned violative products and to be vigilant against it. Always check if a drug product has been registered with the FDA before purchasing it by making use of the embedded *Search* feature of the FDA website accessible at [www.fda.gov.ph](http://www.fda.gov.ph). You may also look for the FDA Registration number on the product label.

All concerned establishments and/or entities are warned not to distribute the above-identified violative drug products until they have already been covered by the appropriate authorization, otherwise, regulatory actions and sanctions shall be strictly pursued.

All Local Government Units (LGUs) and Law Enforcement Agencies (LEAs) are requested to ensure that these products are not sold or made available in their localities or areas of jurisdiction.

For more information and inquiries, please e-mail us at [info@fda.gov.ph](mailto:info@fda.gov.ph). To report continuous sale or distribution of unregistered health products, kindly e-mail us via [report@fda.gov.ph](mailto:report@fda.gov.ph), or through the online reporting facility, **eReport**, at [www.fda.gov.ph/ereport](http://www.fda.gov.ph/ereport). You may also call the Center for Drug Regulation and Research at telephone number (02) 8809-5596. For any suspected adverse drug reaction (ADR), report immediately to FDA through this link: <https://primaryreporting.who-umc.org/Reporting/Reporter?OrganizationID=PH> and fill out all the required fields.

Dissemination of the information to all concerned is request.

  
**ROLANDO ENRIQUE D. DOMINGO, MD, DPBO**  
Undersecretary of Health  
Officer-in-Charge, Director General

DTN: 

20200117114451